查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
基於人工智慧的藥物傳遞的全球市場：預測（2023-2028）
市場調查報告書
商品編碼
1410140

基於人工智慧的藥物傳遞的全球市場：預測（2023-2028）

AI-Driven Drug Delivery Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預測期內，全球人工智慧驅動的藥物輸送市場規模預計將以 34.54% 的複合年成長率成長。

人工智慧驅動的藥物輸送市場改變了製藥和醫療領域的遊戲規則。這個發展中的產業正在利用人工智慧 (AI) 的力量，透過最佳化治療效果和患者結果來徹底改變藥物的傳遞方式。人工智慧驅動的藥物輸送系統使用複雜的演算法來分析患者資料並實現個人化用藥和藥物輸送。這些系統可以透過融合即時病患監測和自適應劑量來改變藥物釋放速率，以確保準確和及時的治療。此外，人工智慧的預測能力將加快藥物研究、處方和管理速度，並縮短新治療方法的上市時間。人工智慧驅動的藥物傳輸市場有望迎來精準醫療和增強患者照護的新時代，能夠提高治療醫囑遵從性、減少副作用並針對特定疾病領域。

人工智慧 (AI) 和機器學習 (ML) 技術的進步促進了人工智慧驅動的藥物輸送市場的成長

人工智慧 (AI) 和機器學習 (ML) 的進步是人工智慧驅動的藥物輸送市場的關鍵市場驅動力。人工智慧和機器學習演算法的不斷進步使得資料分析更加準確和複雜，從而帶來更好的藥物發現、配方和給藥技術。包括患者資訊和藥物交互作用在內的大型資料集可以透過人工智慧驅動的演算法進行分析，以預測適當的給藥方案和個體化治療計劃。人工智慧驅動的藥物輸送系統可以找到即時患者資料中的模式和相關性，以改變藥物釋放速率和給藥方案，從而最大限度地提高治療效果，同時最大限度地減少不良反應。人工智慧和機器學習技術的快速發展正在開闢藥物輸送的新途徑，並改變藥物研究和患者照護的模式。

利用人工智慧改善藥物輸送市場的藥物配方和輸送最佳化

改進藥物配方和遞送最佳化是人工智慧驅動的藥物遞送市場的關鍵成長要素。研究人員可以使用人工智慧 (AI) 和機器學習 (ML) 技術來分析複雜的資料集並深入了解藥理特性和交互作用。這種先進的分析有助於開發更有效的配方，並提高生物有效性和穩定性。人工智慧驅動的給藥系統還可以最佳化給藥方案，確保根據特定患者的需求進行精確和個體化的給藥。透過整合即時患者資料，這些系統可以改變藥物釋放速率和給藥方法，從而改善治療結果並減少副作用。利用人工智慧最佳化藥物成分和輸送系統的能力為更有效、以患者為中心的藥物治療打開了大門。

即時病患監測和自適應劑量將推動人工智慧驅動的藥物傳輸市場規模

即時病患監測和自適應劑量是人工智慧驅動的藥物傳輸市場的關鍵成長要素。透過利用強大的人工智慧 (AI) 和機器學習 (ML) 技術，藥物輸送系統可以持續監測患者反應並調整給藥方案。即時監測能夠及早發現患者狀態的變化，並允許適當地改變藥物輸送。為了個人化藥物劑量並最佳化治療結果，人工智慧主導的自適應劑量會評估個別患者因素，例如年齡、體重和病歷。這種動態策略提高了治療的準確性，減少了副作用，並改善了患者的治療效果。即時病患監測和自適應劑量的結合將改變藥物管理，並開創以患者為中心和響應性藥物治療的新時代。

北美是基於人工智慧的給藥市場的領導者

北美是人工智慧驅動的藥物輸送市場的領導者。該地區的主導地位有多種原因，包括完善的製藥和生物技術產業、強大的研發能力以及注重採用創新技術。此外，人工智慧新興企業與大型製藥企業之間的多種合作關係使北美處於醫療保健領域人工智慧應用的前沿。該地區有利的法律規範和人工智慧研究的高支出正在加速人工智慧系統的發展。然而，市場動態可能會改變人工智慧驅動的藥物傳輸市場的領先地區。

加大人工智慧給藥市場的研發投入

研發投資的增加是人工智慧驅動的藥物輸送市場的促進因素。製藥公司、生物技術公司和研究機構正在大力投資開發人工智慧 (AI) 技術並將其整合到藥物傳輸系統中。這些投資旨在利用人工智慧在最佳化藥物配方、給藥策略和個體化治療方面的前景。此外，行業巨頭和人工智慧公司之間的合作正在推動藥物輸送方面的創造性進步並吸引更多資金。對人工智慧驅動的解決方案日益成長的興趣反映了業界對人工智慧徹底改變藥物開發和改善患者照護的潛力的認知。隨著研究和開發的進展，人工智慧驅動的藥物輸送市場也在不斷發展，為藥物治療提供了新的方法。

主要進展：

2023 年 6 月，默克公司（在美國和加拿大境外稱為 MSD）完成了對 Prometheus Biosciences, Inc.（「Prometheus」）的收購。 Prometheus將成為默克公司的完全子公司，其普通股將不再在納斯達克全球市場上市或交易。 2023 年 6 月，GSK plc 與 BELLUS Health Inc. 建立了合作夥伴關係。葛蘭素史克 (GSK) 宣布，將根據加拿大商業法第 192 條規定，根據清算計劃（以下簡稱“安排”）收購專注於改善難治性慢性咳嗽 (RCC) 患者生活的生物製藥企業 BELLUS公司法。最終決定是根據。 Camry是一種潛在的同類最佳、高選擇性 P2X3拮抗，目前正在進行 3 期測試，作為成年 RCC 患者的一線治療藥物，作為 BELLUS 收購的一部分而宣布。 2023年4月，賽諾菲完成了對Provention Bio的收購。透過本次收購，賽諾菲獲得了治療第1型糖尿病的First-in-Class新藥TZIELD（teplizumab-Azov），擴大了其特色鮮明的非處方藥核心資產組合，推動了向藥品的策略轉型。

公司產品

  • 藥物傳遞：勃林格殷格翰可能正在研究人工智慧驅動的藥物輸送系統，該系統可以針對特異性部位釋放藥物，並增加身體特定區域的藥物濃度。
  • 預測分析：羅氏利用人工智慧來預測藥物反應並識別潛在的副作用，從而有可能實現主動治療並提高患者安全。
  • 個體化治療計畫：葛蘭素史克可能一直在開發一種人工智慧驅動的系統，該系統可以根據特定的患者變數（例如遺傳學、病歷和治療反應）個性化藥物劑量和治療策略。
  • 精準藥物傳遞：默克可能正在探索人工智慧驅動的藥物傳輸系統，該系統可以個性化劑量並調整藥物釋放，以最大限度地提高治療效果。
  • 人工智慧最佳化的配方：諾華可以使用人工智慧演算法來分析生物有效性。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 資訊來源
  • 研究設計

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 業內競爭對手之間的對抗關係
  • 產業價值鏈分析

第5章 基於人工智慧的給藥市場：依技術分類

  • 介紹
  • 機器學習
  • 深度學習
  • 自然語言處理（NLP）
  • 電腦視覺
  • 其他

第6章 基於人工智慧的給藥市場：按給藥類型

  • 介紹
  • 口服給藥
  • 注射給藥
  • 經皮經皮
  • 吸入給藥
  • 植入式藥物輸送
  • 其他

第7章 基於人工智慧的給藥市場：按應用分類

  • 介紹
  • 腫瘤學
  • 糖尿病
  • 心血管疾病
  • 呼吸系統疾病
  • 神經系統疾病
  • 自體免疫疾病
  • 其他

第8章 基於人工智慧的藥物輸送市場：按最終用戶分類

  • 介紹
  • 醫院和診所
  • 製藥公司
  • 研究所和學術中心
  • 居家照護環境
  • 其他
  • 人工智慧驅動的藥物輸送市場：按地區分類
  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 台灣
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 新興企業和市場盈利
  • 併購/協議/合作
  • 供應商競爭力矩陣

第10章 公司簡介

  • MEDTRONIC PLC
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • NOVARTIS AG
  • ELI LILLY AND COMPANY
  • ASTRAZENECA PLC
  • MERCK & CO., INC.
  • PFIZER INC.
  • SANOFI SA
  • JOHNSON & JOHNSON
簡介目錄
Product Code: KSI061615807

The AI-driven drug delivery market is estimated to grow at a CAGR of 34.54% during the forecast period.

The AI-driven drug delivery market is a game changer in the pharmaceutical and healthcare sectors. This developing industry intends to revolutionise medicine delivery methods by using the power of artificial intelligence (AI) and optimising treatment efficacy and patient outcomes. AI-powered medication delivery systems analyse patient data using sophisticated algorithms, enabling personalised dosage and drug administration. These systems may alter medication release rates by merging real-time patient monitoring with adaptive dosage, guaranteeing accurate and timely therapeutic treatments. Furthermore, AI's predictive powers expedite drug research, formulation, and administration, reducing time-to-market for new treatments. The AI-driven drug delivery market, with the ability to increase treatment adherence, decrease side effects, and target particular disease areas, promises to usher in a new age of precision medicine and enhanced patient care.

Advancements in Artificial Intelligence (AI) and Machine Learning (ML) Technologies Enhance the AI-Driven Drug Delivery Market Growth.

Artificial intelligence (AI) and machine learning (ML) advancements are significant development drivers in the AI-driven drug delivery market. The constant progress of AI and ML algorithms has enabled more precise and sophisticated data analysis, resulting in better medicine discovery, formulation, and delivery techniques. Large datasets, including patient information and medication interactions, may be analysed by AI-powered algorithms to anticipate appropriate dosage regimens and personalised treatment plans. AI-driven medication delivery systems may alter drug release rates and dosage regimens by finding patterns and correlations in real-time patient data, maximising therapeutic efficacy while minimising unwanted effects. The fast advancement of AI and ML technologies has opened up new avenues for medication delivery, altering the landscape of pharmaceutical research and patient care.

Improved Drug Formulation and Delivery Optimization in AI-Driven Drug Delivery Market.

In the AI-driven drug delivery market, improved medication formulation and delivery optimisation are important growth factors. Researchers can analyse complicated data sets using artificial intelligence (AI) and machine learning (ML) techniques to get insights about pharmacological characteristics and interactions. This sophisticated analysis contributes to the development of more efficient medication formulations with improved bioavailability and stability. AI-powered medication delivery systems optimise dose regimens as well, guaranteeing accurate and personalised administration customised to specific patient demands. These systems can alter medication release rates and administration modalities by incorporating real-time patient data, resulting in enhanced treatment results and lower side effects. The capacity to use AI to optimise medication compositions and delivery systems opens the door to more effective and patient-centred pharmacological therapies.

Real-Time Patient Monitoring and Adaptive Dosing Boosts the AI-Driven Drug Delivery Market Size.

In the AI-driven drug delivery market, real-time patient monitoring and adaptive dosage are critical growth factors. Drug delivery systems can continually monitor patient reactions and adjust dose regimens by utilising powerful artificial intelligence (AI) and machine learning (ML) technology. Real-time monitoring provides for the early detection of changes in patient circumstances, allowing for appropriate drug delivery modifications. To personalise medicine dose and optimise treatment performance, AI-driven adaptive dosing evaluates individual patient factors such as age, weight, and medical history. This dynamic strategy increases treatment accuracy, decreases side effects, and improves patient outcomes. The combination of real-time patient monitoring and adaptive dosage transforms medication administration, ushering in a new era of patient-centred and responsive pharmacological treatments.

North America is the Market Leader in the AI-Driven Drug Delivery Market.

North America was regarded as the market leader in the AI-driven drug delivery market. Several reasons contribute to the region's supremacy, including its well-established pharmaceutical and biotechnology sectors, substantial research and development skills, and a strong emphasis on embracing innovative technologies. Furthermore, with multiple collaborations between AI startups and major pharmaceutical corporations, North America has been at the forefront of AI applications in healthcare. The region's favourable regulatory framework and significant expenditures in AI research have hastened the development of AI-driven drug Delivery systems. However, market dynamics may change the top region in the AI-driven drug delivery market.

Increased Research and Development Investments in AI-Driven Drug Delivery Market.

Increased R&D investments are driving factors in the AI-driven drug delivery market. Pharmaceutical businesses, biotechnology firms, and research institutes are investing heavily in developing and integrating artificial intelligence (AI) technologies into drug delivery systems. These investments seek to capitalise on the promise of AI in optimising medication formulations, dosage tactics, and personalised therapies. Furthermore, cooperation between industry heavyweights and AI companies is fuelling creative advances in medicine delivery, garnering further financing. The increased interest in AI-driven solutions reflects the industry's acknowledgement of AI's potential to revolutionise medication development and improve patient care. As R&D efforts develop, the AI-driven drug delivery market evolves, providing novel ways to pharmaceutical therapies.

Key Developments:

  • In June 2023, Merck, known as MSD outside of the United States and Canada, completed the purchase of Prometheus Biosciences, Inc. ("Prometheus"). Prometheus has become a wholly owned subsidiary of Merck, and its common stock will no longer be listed or traded on the Nasdaq Global Market.
  • In June 2023, GSK plc and BELLUS Health Inc. established a collaboration. GSK has finalised its purchase of BELLUS, a biopharmaceutical business dedicated to improving the lives of patients suffering from refractory chronic cough (RCC), under a plan of arrangement under Section 192 of the Canada Business Corporations Act (the "Arrangement"). Camlipixant, a possible best-in-class and highly selective P2X3 antagonist now in phase III research for the first-line treatment of adult patients with RCC, was announced as part of the BELLUS purchase.
  • In April 2023, Sanofi completed its acquisition of ProventionBio, Inc. ("Provention Bio"). The purchase expands Sanofi's core asset portfolio in General Medicines with the addition of TZIELD (teplizumab-Azov), a novel, wholly owned, first-in-class medication in type 1 diabetes, and furthers the company's strategy shift towards medicines with a distinctive profile.

Company Products:

  • Targeted Drug Delivery: Boehringer Ingelheim may have been investigating AI-driven drug delivery systems that allow for targeted and site-specific medication release, hence increasing drug concentration in certain parts of the body.
  • Predictive Analytics: Roche may have used artificial intelligence to anticipate drug reactions and identify probable side effects, allowing for pre-emptive treatments and enhanced patient safety.
  • Personalized Treatment Plans: GSK might have been working on AI-powered systems to personalise medicine doses and treatment strategies based on specific patient variables including genetics, medical history, and treatment response.
  • Precision Drug Delivery: Merck may have been investigating AI-powered medication delivery systems that allow for personalized dosage and tailored drug release, hence maximizing therapeutic effects.
  • AI-Optimized Drug Formulations: Novartis may be using AI algorithms to analyze medication characteristics and interactions, which might lead to the creation of optimized drug formulations with enhanced bioavailability and stability.

Segmentation:

By Technology

  • Machine Learning
  • Deep Learning
  • Natural Language Processing (Nlp)
  • Computer Vision
  • Others

By Type Of Drug Delivery

  • Oral Drug Delivery
  • Injectable Drug Delivery
  • Transdermal Drug Delivery
  • Inhalation Drug Delivery
  • Implantable Drug Delivery
  • Others

By Application

  • Oncology
  • Diabetes
  • Cardiovascular Diseases
  • Respiratory Disorders
  • Neurological Disorders
  • Autoimmune Diseases
  • Others

By End-User

  • Hospitals And Clinics
  • Pharmaceutical Companies
  • Research Institutes And Academic Centers
  • Home Care Settings
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Sources
  • 2.3. Research Design

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. AI-DRIVEN DRUG DELIVERY MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. MACHINE LEARNING
  • 5.3. DEEP LEARNING
  • 5.4. NATURAL LANGUAGE PROCESSING (NLP)
  • 5.5. COMPUTER VISION
  • 5.6. OTHERS

6. AI-DRIVEN DRUG DELIVERY MARKET, BY TYPE OF DRUG DELIVERY

  • 6.1. Introduction
  • 6.2. ORAL DRUG DELIVERY
  • 6.3. INJECTABLE DRUG DELIVERY
  • 6.4. TRANSDERMAL DRUG DELIVERY
  • 6.5. INHALATION DRUG DELIVERY
  • 6.6. IMPLANTABLE DRUG DELIVERY
  • 6.7. OTHERS

7. AI-DRIVEN DRUG DELIVERY MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. ONCOLOGY
  • 7.3. DIABETES
  • 7.4. CARDIOVASCULAR DISEASES
  • 7.5. RESPIRATORY DISORDERS
  • 7.6. NEUROLOGICAL DISORDERS
  • 7.7. AUTOIMMUNE DISEASES
  • 7.8. OTHERS

8. AI-DRIVEN DRUG DELIVERY MARKET, BY END-USER

  • 8.1. Introduction
  • 8.2. HOSPITALS AND CLINICS
  • 8.3. PHARMACEUTICAL COMPANIES
  • 8.4. RESEARCH INSTITUTES AND ACADEMIC CENTERS
  • 8.5. HOME CARE SETTINGS
  • 8.6. OTHERS
  • 8.7. AI-DRIVEN DRUG DELIVERY MARKET, BY GEOGRAPHY
  • 8.8. Introduction
  • 8.9. North America
    • 8.9.1. United States
    • 8.9.2. Canada
    • 8.9.3. Mexico
  • 8.10. South America
    • 8.10.1. Brazil
    • 8.10.2. Argentina
    • 8.10.3. Others
  • 8.11. Europe
    • 8.11.1. United Kingdom
    • 8.11.2. Germany
    • 8.11.3. France
    • 8.11.4. Italy
    • 8.11.5. Spain
    • 8.11.6. Others
  • 8.12. Middle East and Africa
    • 8.12.1. Saudi Arabia
    • 8.12.2. UAE
    • 8.12.3. Others
  • 8.13. Asia Pacific
    • 8.13.1. Japan
    • 8.13.2. China
    • 8.13.3. India
    • 8.13.4. South Korea
    • 8.13.5. Indonesia
    • 8.13.6. Taiwan
    • 8.13.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. MEDTRONIC PLC
  • 10.2. F. HOFFMANN-LA ROCHE AG
  • 10.3. GLAXOSMITHKLINE PLC
  • 10.4. NOVARTIS AG
  • 10.5. ELI LILLY AND COMPANY
  • 10.6. ASTRAZENECA PLC
  • 10.7. MERCK & CO., INC.
  • 10.8. PFIZER INC.
  • 10.9. SANOFI S.A.
  • 10.10. JOHNSON & JOHNSON